1. Imaging of Colorectal Liver Metastasis.
- Author
-
Baghdadi A, Mirpour S, Ghadimi M, Motaghi M, Hazhirkarzar B, Pawlik TM, and Kamel IR
- Subjects
- Bevacizumab, Hepatectomy, Humans, Magnetic Resonance Imaging, Positron Emission Tomography Computed Tomography, Colorectal Neoplasms diagnostic imaging, Colorectal Neoplasms pathology, Liver Neoplasms diagnostic imaging, Liver Neoplasms secondary
- Abstract
Colorectal cancer (CRC) is one of the most common cancers in the world. The most important determinant of survival and prognosis is the stage and presence of metastasis. The liver is the most common location for CRC metastasis. The only curative treatment for CRC liver metastasis (CRLM) is resection; however, many patients are ineligible for surgical resection of CRLM. Locoregional treatments such as ablation and intra-arterial therapy are also available for patients with CRLM. Assessment of response after chemotherapy is challenging due to anatomical and functional changes. Antiangiogenic agents such as bevacizumab that are used in the treatment of CRLM may show atypical patterns of response on imaging. It is vital to distinguish patterns of response in addition to toxicities to various treatments. Imaging plays a critical role in evaluating the characteristics of CRLM and the approach to treatment. CT is the modality of choice in the diagnosis and management of CRLM. MRI is best used for indeterminate lesions and to assess response to intra-arterial therapy. PET-CT is often utilized to detect extrahepatic metastasis. State-of-the-art imaging is critical to characterize patterns of response to various treatments. We herein review the imaging characteristics of CRLM with an emphasis on imaging changes following the most common CRLM treatments., (© 2021. The Society for Surgery of the Alimentary Tract.)
- Published
- 2022
- Full Text
- View/download PDF